Proteolysis targeting chimera technology: a novel strategy for treating diseases of the central nervous system.

Proteolysis targeting chimera technology: a novel strategy for treating diseases of the central nervous system.
复制标题

靶向嵌合体技术的蛋白水解:治疗中枢神经系统疾病的新策略

DOI:
10.4103/1673-5374.308075
复制
发表时间:
2021-10
影响因子:
6.1
通讯作者:
Zhou SL
Zhou SL
中科院分区:
医学2区
文献类型:
--
作者:
Ma K;Han XX;Yang XM;Zhou SL

文献摘要

参考文献

被引文献

相似文献

Neurological diseases such as stroke, Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease are among the intractable diseases for which appropriate drugs and treatments are lacking. Proteolysis targeting chimera (PROTAC) technology is a novel strategy to solve this problem. PROTAC technology uses the ubiquitin-protease system to eliminate mutated, denatured, and harmful proteins in cells. It can be reused, and utilizes the protein destruction mechanism of the cells, thus making up for the deficiencies of traditional protein degradation methods. It can effectively target and degrade proteins, including proteins that are difficult to identify and bind. Therefore, it has extremely important implications for drug development and the treatment of neurological diseases. At present, the targeted degradation of mutant BTK, mHTT, Tau, EGFR, and other proteins using PROTAC technology is gaining attention. It is expected that corresponding treatment of nervous system diseases can be achieved. This review first focuses on the recent developments in PROTAC technology in terms of protein degradation, drug production, and treatment of central nervous system diseases, and then discusses its limitations. This review will provide a brief overview of the recent application of PROTAC technology in the treatment of central nervous system diseases.
DOI: 10.18632/oncotarget.7043
发表时间: 2016-09-27
期刊: Oncotarget
影响因子: --
作者:
de Melo Gagliato D;Jardim DL;Marchesi MS;Hortobagyi GN
通讯作者: Hortobagyi GN
DOI: 10.2174/1570159x16666180222155833
发表时间: 2018
影响因子: 5.3
作者:
Duris K;Splichal Z;Jurajda M
通讯作者: Jurajda M
DOI: 10.1016/j.molcel.2017.02.027
发表时间: 2017-04-06
期刊: Molecular cell
影响因子: 16
作者:
Hsu SC;Gilgenast TG;Bartman CR;Edwards CR;Stonestrom AJ;Huang P;Emerson DJ;Evans P;Werner MT;Keller CA;Giardine B;Hardison RC;Raj A;Phillips-Cremins JE;Blobel GA
通讯作者: Blobel GA
DOI: 10.1002/anie.201307761
发表时间: 2014-02-24
影响因子: 16.6
作者:
Buckley, Dennis L.;Crews, Craig M.
通讯作者: Crews, Craig M.
DOI: 10.1016/j.ccell.2019.10.002
发表时间: 2019-11-11
期刊: CANCER CELL
影响因子: 50.3
作者:
Bai, Longchuan;Zhou, Haibin;Wang, Shaomeng
通讯作者: Wang, Shaomeng